1484PD - Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

Autor:	Mok, T.S.K. 1, Shaw, A.T. 2, Camidge, R.D. 3, Gadgeel, S.M. 4, Rosell, R. 5, Dziadziuszko, R. 6, Kim, D.-W. 7, Perol, M. 8, Ou, S.-H. 9, Bordogna, W. 10, Smoljanović, V. 10, Hilton, M. 10, Peters, S. 11
Zdroj:	In Annals of Oncology October 2019 30 Supplement 5:v607-v607
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu